Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : IMM-BCP-01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Immunome
Deal Size : $13.3 million
Deal Type : Partnership
Details : Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
Product Name : IMM-BCP-01
Product Type : Large molecule
Upfront Cash : Undisclosed
February 03, 2021
Lead Product(s) : IMM-BCP-01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Immunome
Deal Size : $13.3 million
Deal Type : Partnership
Reset All
